Expand URGN Menu
URGN MENU

URGN Latest Press Releases

-- June 2, 2026 --

UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO (mitomycin) for pyelocalyceal solution Globe Newswire 8:00 AM

-- June 1, 2026 --

UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference Globe Newswire 4:10 PM

-- May 15, 2026 --

UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC Globe Newswire 8:00 AM

-- May 13, 2026 --

ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial Globe Newswire 8:00 AM

-- May 7, 2026 --

UroGen Pharma to Present at Upcoming Investor Conferences Globe Newswire 8:00 AM

-- May 6, 2026 --

UroGen Reports ZUSDURI Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights Globe Newswire 8:00 AM

-- April 29, 2026 --

UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026 Globe Newswire 8:00 AM

-- April 8, 2026 --

UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer Globe Newswire 8:00 AM

-- March 30, 2026 --

Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI Globe Newswire 8:00 AM

-- March 13, 2026 --

UroGen Applauds BCAN's New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence Globe Newswire 8:00 AM

-- March 6, 2026 --

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:10 PM

-- March 2, 2026 --

UroGen Announces ZUSDURI Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results Globe Newswire 8:00 AM
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors Globe Newswire 7:55 AM

-- February 27, 2026 --

ZUSDURI Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC Globe Newswire 8:30 AM

-- February 24, 2026 --

UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference Globe Newswire 4:05 PM

-- February 23, 2026 --

UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026 Globe Newswire 8:00 AM

-- February 4, 2026 --

UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit Globe Newswire 8:00 AM

-- January 5, 2026 --

Permanent J Code for ZUSDURI Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes